Isatuximab Plus Pomalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma in Real-Life Context in France: IMAGE Subgroup Analysis Based on Prior Lines of Therapy and Refractory Status - Archive ouverte HAL Accéder directement au contenu
Communication Dans Un Congrès Année : 2022

Dates et versions

hal-04071492 , version 1 (17-04-2023)

Identifiants

Citer

Olivier Decaux, Radhia Lafore, Daniel Iaquinta, Christina Tekle, Xavier Leleu. Isatuximab Plus Pomalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma in Real-Life Context in France: IMAGE Subgroup Analysis Based on Prior Lines of Therapy and Refractory Status. 64th ASH Annual Meeting and Exposition, Dec 2022, New Orleans, United States. pp.10969-10970, ⟨10.1182/blood-2022-162602⟩. ⟨hal-04071492⟩
17 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More